CAMBRIDGE, Mass., April 19 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM) will hold a live webcast of its
conference call at 8:00 a.m. ET on Thursday, April 26, 2007. Dr. Deborah
Dunsire, Chief Executive Officer, will host the call. Senior management
will discuss the Company's first-quarter 2007 financial results and
additional corporate activities. A presentation to accompany the conference
call will also be available on the webcast. The Company will announce its
financial results for this period in a press release to be issued on
Thursday, April 26, 2007.prior to the conference call.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
The press release, presentation and the live webcast can be accessed by
visiting the Investors section of the Company's website,
http://www.millennium.com. Following the webcast, an archived version of
the call will be available at the same address for 30 days.
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company
based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a
novel cancer product, and has a robust clinical development pipeline of
product candidates. The Company's research, development and
commercialization activities are focused in two therapeutic areas: oncology
and inflammation. By applying its knowledge of the human genome,
understanding of disease mechanisms and industrialized drug discovery
platform, Millennium is developing an exciting pipeline of innovative
product candidates. The Company's website is http://www.millennium.com.
Contact:
Kyle Kuvalanka
Investor Relations
(617) 761-4734
Editors' Note: This press release is also available under the Media
section of the Company's website at: http://www.millennium.com.
SOURCE Millennium Pharmaceuticals, Inc.
 back to top
Related links:
http://www.millennium.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO
AP Archive: http://photoarchive.ap.org PRN Photo Desk
photodesk@prnewswire.com
http://www.prnewswire.com/comp/114562.html /
CONTACT:
Kyle Kuvalanka, Investor Relations,
Millennium Pharmaceuticals, Inc. +1-617-761-4734
|
